Biomarin Pharmaceutical (BMRN) FY2012 results: revenue $501 million, up 13.5% on the year
Biomarin Pharmaceutical Inc. (BMRN) reported revenue of $501 million for fiscal 2012, the year ended 31 December 2012, up 13.5% on the year before. Net income was -$114 million, and diluted earnings per share $-0.95. The figures are the company's own, from the 10-K it filed with the SEC on 26 February 2013.
Revenue
$501 million
+13.5% on the year
FY2008FY2012
Operating margin
-22.0%
-7.7% a year earlier
FY2008FY2012
Net income
-$114 million
FY2008FY2012
Diluted EPS
-$0.95
FY2008FY2012
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2012
FY2011
FY2010
On the year
Last 8 years
Revenue
501
441
376
+13.5%
Cost of revenue
91.8
84.0
70.3
+9.3%
Gross profit
409
357
306
+14.4%
Gross margin
81.7%
81.0%
81.3%
Research and development
302
214
147
+41.0%
Selling, general and administrative
198
175
152
+13.0%
Operating income
-110
-33.9
0.5
Operating margin
-22.0%
-7.7%
0.1%
Interest expense
7.6
8.4
10.8
-9.2%
Pre-tax income
-118
-43.6
-21.5
Income tax
-3.9
10.2
-227
Net income
-114
-53.8
206
Net margin
-22.8%
-12.2%
54.7%
Diluted EPS
-$0.95
-$0.48
$1.73
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2012
FY2011
FY2010
On the year
Last 8 years
Operating cash flow
17.6
18.4
18.7
-4.4%
Capital expenditure
44.6
73.2
49.5
-39.1%
Free cash flow
-27.0
-54.8
-30.7
Free cash flow margin
-5.4%
-12.4%
-8.2%
Cash from investing
-196
-89.6
-101
Cash from financing
312
29.3
3.5
+964.5%
Depreciation and amortisation
44.3
35.0
27.7
+26.5%
Share-based compensation
47.3
43.9
38.4
+7.8%
Diluted shares, weighted
120m
112m
126m
+7.3%
Shares outstanding at period end
126m
115m
111m
+9.6%
Balance sheet
$ million
FY2012
FY2011
FY2010
On the year
Last 8 years
Shareholders' equity
1,016
773
717
+31.4%
Debt
348
348
378
-0.0%
Other liabilities
204
182
168
+12.1%
Total liabilities and equity
1,568
1,304
1,263
+20.3%
Fixed assets
284
269
222
+5.8%
Goodwill
51.5
51.5
53.4
0.0%
Intangible assets
163
180
104
-9.6%
Investments
383
243
314
+57.6%
Cash and equivalents
181
46.3
88.1
+290.1%
Receivables
109
105
86.6
+4.0%
Inventory
129
130
110
-1.1%
Other assets
268
278
285
-3.8%
Total assets
1,568
1,304
1,263
+20.3%
10-K for the year ended 31 December 2012, filed 26 February 2013: the filing.